The role of bevacizumab in the treatment of glioblastoma

  title={The role of bevacizumab in the treatment of glioblastoma},
  author={Roberto Jose Diaz and Sheikh C. Ali and Mehreen Gull Qadir and Macarena de la Fuente and Michael E. Ivan and Ricardo J. Komotar},
  journal={Journal of Neuro-Oncology},
Bevacizumab has been used in patients with GBM as a salvage therapy since its approval in the United States for recurrent GBM in 2009. In order to review the therapeutic effect of bevacizumab in the primary and recurrent clinical setting we have performed a systematic analysis of data from the published literature. Weighted median progression free survival and overall survival were calculated and compared to standard therapy or other experimental therapies. A qualitative analysis of the limited… 

Update on Chemotherapeutic Approaches and Management of Bevacizumab Usage for Glioblastoma

The clinical impact of bevacizumab for glioblastoma treatment is discussed by reviewing previous clinical trials and real-world evidence by focusing on Japanese experiences, and suggestions for updating the approaches and management are provided.

Bevacizumab for Patients with Recurrent Multifocal Glioblastomas

Evaluated whether the course of disease differs in glioblastoma patients with a multifocal disease pattern compared to those with a single lesion only, and investigated whether BEV therapy affects the invasive growth pattern as measured by the appearance of new lesions on magnetic resonance imaging (MRI).

Phase II Study of Bevacizumab and Vorinostat for Patients with Recurrent World Health Organization Grade 4 Malignant Glioma

This phase II, single‐center, nonrandomized study evaluated the efficacy of BEV combined with histone deacetylase inhibitor vorinostat (VOR) in recurrent GBM and found that combination treatment ofBEV and VOR was well tolerated.

Efficacy of bevacizumab combined with temozolomide dose-dense regimen on recurrent glioma.

Bvacizumab combined with temozolomide can significantly improve the clinical efficacy, increase the quality of life of patients, and delay the progression of recurrent glioma, with tolerable adverse reactions.

Days gained response discriminates treatment response in patients with recurrent glioblastoma receiving bevacizumab-based therapies

Days Gained has significant meaning in recurrent therapy as a metric of treatment response, even in the context of anti-angiogenic therapies, supporting the use of DG as an adjunct response metric that quantitatively connects treatment response and clinical outcomes.

Glioblastoma Treatment with Temozolomide and Bevacizumab and Overall Survival in a Rural Tertiary Healthcare Practice

Background The efficacy of temozolomide (TMZ) chemotherapy for treating newly diagnosed glioblastoma (GBM), a primary brain tumor with short survival, was demonstrated in a clinical trial in 2005,

Bevacizumab in recurrent high-grade glioma: a single institution retrospective analysis on 92 patients

The analysis confirms the efficacy of bevacizumab in recurrent high-grade glioma patients with an acceptable toxicity profile, in keeping with its known safety in the literature.

A predictive value of von Willebrand factor for early response to Bevacizumab therapy in recurrent glioma

Bevacizumab (BV), a neutralizing monoclonal antibody against the vascular endothelial growth factor ligand, is recognized as a potent anti-angiogenic agent with antitumor activity. The aim of this

Anti-PD-1, anti-VEGF, and temozolomide therapy in a patient with recurrent glioblastoma: a case report

The experience of this complicated case indicates the possible application of immune checkpoint inhibitors, anti-angiogenesis agents, and cytotoxic reagents for recurrent glioblastoma.

A systematic review of the utility of amino acid PET in assessing treatment response to bevacizumab in recurrent high-grade glioma

Abstract Background. Currently, bevacizumab (BEV), an antiangiogenic agent, is used as an adjunctive therapy to re-irradiation and surgery in patients with recurrent high-grade gliomas (rHGG). BEV



Bevacizumab and chemotherapy for recurrent glioblastoma

A retrospective analysis of patients treated for recurrent glioblastoma with bevacizumab vs a control group of patients comparing progression-free survival (PFS) and overall survival (OS) between the two groups, and performed subgroup analysis based on age and performance status.

Bevacizumab Improves Quality of Life in Patients with Recurrent Glioblastoma

BEV increases independent living and lengthens overall survival after GBM recurrence and reduction in steroid dose may contribute to prolonged independence.

Can bevacizumab prolong survival for glioblastoma patients through multiple lines of therapy?

A novel study aims to evaluate whether continuing bevacizumab plus lomustine (as second-line therapy) and SOC (third line and beyond) improves survival compared with placebo plus lmustine and then placebo plus SOC in patients with glioblastoma who progressed after first-line bevacanalyst plus SOC.

A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy

The combination of bevacizumab and irinotecan is well tolerated and moderately efficacious in glioblastoma and glioma WHO gr.

A randomized trial of bevacizumab for newly diagnosed glioblastoma.

First-line use of bevacizumab did not improve overall survival in patients with newly diagnosed glioblastoma, and progression-free survival was prolonged but did not reach the prespecified improvement target.

Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme.

This study failed to detect activity of such a combination in patients with progressive GBM beyond bevacizumab therapy, and found that temsirolimus can be safely administered in combination with bevacsimab.

A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma.

The addition of bevacizumab to conventional therapy in newly diagnosed glioblastoma appears to improve both PFS and OS in patients with newly diagnosed GBM, with acceptable morbidity.

Bevacizumab in combination with radiotherapy and temozolomide for patients with newly diagnosed glioblastoma multiforme.

Combination of bevacizumab with radiotherapy and TMZ is safe and feasible in patients with newly diagnosed GBM, but because of low response rates, this treatment strategy does not favor a neoadjuvant approach.

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.

Bvacizumab, alone or in combination with irinotecan, was well tolerated and active in recurrent glioblastoma in a phase II, multicenter, open-label, noncomparative trial.

Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO (Italian Association of Neuro-Oncology)

This study failed to demonstrate a superiority of the combination of bevacizumab and fotemustine over either bev ACIZumab or fotEMustine alone as historical controls, and future studies should explore alternative regimens of combination of the two drugs.